WO2005102309A3 - In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration - Google Patents

In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration Download PDF

Info

Publication number
WO2005102309A3
WO2005102309A3 PCT/IB2005/001118 IB2005001118W WO2005102309A3 WO 2005102309 A3 WO2005102309 A3 WO 2005102309A3 IB 2005001118 W IB2005001118 W IB 2005001118W WO 2005102309 A3 WO2005102309 A3 WO 2005102309A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukotriene
administration
ltb4
vivo release
endogenous anti
Prior art date
Application number
PCT/IB2005/001118
Other languages
French (fr)
Other versions
WO2005102309A2 (en
Inventor
Jean Gosselin
Louis Flamand
Pierre Borgeat
Original Assignee
Ltb4 Sweden Ab
Jean Gosselin
Louis Flamand
Pierre Borgeat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltb4 Sweden Ab, Jean Gosselin, Louis Flamand, Pierre Borgeat filed Critical Ltb4 Sweden Ab
Publication of WO2005102309A2 publication Critical patent/WO2005102309A2/en
Publication of WO2005102309A3 publication Critical patent/WO2005102309A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators.
PCT/IB2005/001118 2004-04-26 2005-04-26 In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration WO2005102309A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56494704P 2004-04-26 2004-04-26
US60/564,947 2004-04-26

Publications (2)

Publication Number Publication Date
WO2005102309A2 WO2005102309A2 (en) 2005-11-03
WO2005102309A3 true WO2005102309A3 (en) 2006-05-18

Family

ID=34956563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001118 WO2005102309A2 (en) 2004-04-26 2005-04-26 In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration

Country Status (2)

Country Link
US (1) US20050239889A1 (en)
WO (1) WO2005102309A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US20130236496A1 (en) * 2010-06-29 2013-09-12 Universite De Laval Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
MA41120A (en) 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
WO2017013492A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
SG11201805149XA (en) 2015-12-18 2018-07-30 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029751A1 (en) * 1996-02-15 1997-08-21 Virocell Inc. Use of leukotriene b4 or its analogues as antiviral and antineoplastic agents
WO1998024397A2 (en) * 1996-12-03 1998-06-11 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
AU718069B2 (en) * 1993-05-28 2000-04-06 Suntory Holdings Limited Prevention and improvement of medical symptoms caused by leucotriene B4
WO2001028532A2 (en) * 1999-10-19 2001-04-26 Kain Kevin C Methods and compositions for predicting, diagnosing and treating lipodystrophy
US20020028848A1 (en) * 2000-04-07 2002-03-07 Michael Buchanan Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
WO2002059072A2 (en) * 2001-01-02 2002-08-01 New York Medical College 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
WO2003004054A1 (en) * 2001-07-05 2003-01-16 Virocell Inc. Ltb4 as vaccine aduvant
US20030191184A1 (en) * 2001-12-18 2003-10-09 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
WO2004112795A1 (en) * 2003-06-25 2004-12-29 Ltb4 Sweden Ab Ltb4 compositions for treating tract infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8606719D0 (en) * 1986-03-19 1986-04-23 Lister Preventive Med Genetic probes
EP0402400B1 (en) * 1988-02-18 1999-09-08 University of Utah Genetic identification employing dna probes of variable number tandem repeat loci
US4963663A (en) * 1988-12-23 1990-10-16 University Of Utah Genetic identification employing DNA probes of variable number tandem repeat loci
US5766847A (en) * 1988-10-11 1998-06-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for analyzing length polymorphisms in DNA regions
US5582979A (en) * 1989-04-21 1996-12-10 Marshfield Clinic Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5364759B2 (en) * 1991-01-31 1999-07-20 Baylor College Medicine Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5599666A (en) * 1994-03-28 1997-02-04 Promega Corporation Allelic ladders for short tandem repeat loci
US5843660A (en) * 1994-09-30 1998-12-01 Promega Corporation Multiplex amplification of short tandem repeat loci
US6479235B1 (en) * 1994-09-30 2002-11-12 Promega Corporation Multiplex amplification of short tandem repeat loci
US6013444A (en) * 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU718069B2 (en) * 1993-05-28 2000-04-06 Suntory Holdings Limited Prevention and improvement of medical symptoms caused by leucotriene B4
WO1997029751A1 (en) * 1996-02-15 1997-08-21 Virocell Inc. Use of leukotriene b4 or its analogues as antiviral and antineoplastic agents
US6093741A (en) * 1996-02-15 2000-07-25 Virocell Inc. Agents with leukotriene B4-like activity as antiherpes viral agents
WO1998024397A2 (en) * 1996-12-03 1998-06-11 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
WO2001028532A2 (en) * 1999-10-19 2001-04-26 Kain Kevin C Methods and compositions for predicting, diagnosing and treating lipodystrophy
US20020028848A1 (en) * 2000-04-07 2002-03-07 Michael Buchanan Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
WO2002059072A2 (en) * 2001-01-02 2002-08-01 New York Medical College 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
WO2003004054A1 (en) * 2001-07-05 2003-01-16 Virocell Inc. Ltb4 as vaccine aduvant
US20030191184A1 (en) * 2001-12-18 2003-10-09 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
WO2004112795A1 (en) * 2003-06-25 2004-12-29 Ltb4 Sweden Ab Ltb4 compositions for treating tract infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FLAMAND LOUIS ET AL: "Release of anti-HIV mediators after administration of leukotriene B4 to humans", JOURNAL OF INFECTIOUS DISEASES, vol. 189, no. 11, 1 June 2004 (2004-06-01), pages 2001 - 2009, XP008059102, ISSN: 0022-1899 *
GEWIRZT A T ET AL: "Pathogen-induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A4 Analogs", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 101, no. 9, May 1998 (1998-05-01), pages 1860 - 1869, XP002141528, ISSN: 0021-9738 *
MENARD ARMELLE ET AL: "The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A-4 hydrolase and metallopeptidase inhibitors", BIOCHEMICAL JOURNAL, vol. 320, no. 2, 1996, pages 687 - 691, XP002364824, ISSN: 0264-6021 *
NOVERR MAIRI C ET AL: "Regulation of Candida albicans morphogenesis by fatty acid metabolites.", INFECTION AND IMMUNITY. NOV 2004, vol. 72, no. 11, November 2004 (2004-11-01), pages 6206 - 6210, XP008044878, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2005102309A2 (en) 2005-11-03
US20050239889A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005102309A3 (en) In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
WO2006099379A3 (en) Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2009153496A3 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2006015035A8 (en) Useful compounds for hpv infection
WO2006087759A3 (en) Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
IL195142A (en) Substituted arylimidazolone and triazolone, process for their preparation and pharmaceutical compositions comprising the same for the treatment or prophylaxis of diseases
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2010028132A3 (en) Novel choline cocrystal of epalrestat
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2008132021A3 (en) Fungicide mixtures
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase